CNCE - Concert Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.01
+0.77 (+5.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.24
Open14.34
Bid12.00 x 800
Ask16.94 x 1300
Day's Range14.29 - 15.04
52 Week Range10.80 - 26.15
Volume113,666
Avg. Volume163,567
Market Cap351.675M
Beta (3Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-1.78
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.50
Trade prices are not sourced from all markets
  • Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check
    Simply Wall St.3 days ago

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Zero-debt allows substantial financial flexibility, especially forRead More...

  • GlobeNewswire4 days ago

    Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire5 days ago

    Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

    Concert Pharmaceuticals, Inc. (CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata.

  • Mizuho's 9 Best Biotech Stocks to Buy for 2019
    Kiplinger10 days ago

    Mizuho's 9 Best Biotech Stocks to Buy for 2019

    Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Business Wire23 days ago

    Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 single-ascending dose trial will evaluate the safety, tolerability, and pharmacokinetic profile of CTP-692 in healthy volunteers. “For decades all approved schizophrenia drugs have acted predominantly by modulation of dopamine, or dopamine and serotonin receptors.

  • Business Wire25 days ago

    Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata. The trial previously enrolled patients to receive 4 mg and 8 mg twice daily compared to placebo. Data from the Phase 2a trial including the 12 mg cohort is expected in the third quarter of 2019.

  • How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares?
    Simply Wall St.last month

    How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)?
    Insider Monkey2 months ago

    Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)?

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]

  • Business Wire2 months ago

    Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor, which has been demonstrated to be important to mood, memory, and cognition. Concert’s Phase 1 program will include a crossover pharmacokinetic comparison of CTP-692 to D-serine and single- and multiple-ascending dose studies to assess the safety, tolerability and pharmacokinetic profile of CTP-692 in healthy volunteers.

  • Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
    Zacks3 months ago

    Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.

  • Should You Be Concerned About Concert Pharmaceuticals Inc’s (NASDAQ:CNCE) Historical Volatility?
    Simply Wall St.3 months ago

    Should You Be Concerned About Concert Pharmaceuticals Inc’s (NASDAQ:CNCE) Historical Volatility?

    If you own shares in Concert Pharmaceuticals Inc (NASDAQ:CNCE) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Business Wire3 months ago

    Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata

    At 24 weeks, patients treated with an 8 mg twice-daily dose of CTP-543 met the primary efficacy endpoint vs. placebo (p

  • Business Wire3 months ago

    Concert Pharmaceuticals to Participate at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. today announced that it will participate at the following upcoming investor conferences:

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT

    Q3 2018 Concert Pharmaceuticals Inc Earnings Call

  • Business Wire3 months ago

    Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine

    Concert Pharmaceuticals, Inc. (CNCE) today presented preclinical results that support the potential of CTP-692, the Company’s novel drug candidate for schizophrenia, to improve the safety profile of D-serine. CTP-692 is a deuterated form of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor. In preclinical evaluation, Concert demonstrated that selective deuterium modification resulted in increased exposure of CTP-692 compared to a similar dose of D-serine.

  • Associated Press4 months ago

    Concert: 3Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 74 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire4 months ago

    Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update

    Conference Call Scheduled Today at 8:30 a.m. ET

  • Business Wire4 months ago

    Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and provide a business update. A live webcast of the third quarter financial results may be accessed in the Investors section of the Company’s website at www.concertpharma.com.

  • Simply Wall St.4 months ago

    What is Behind Concert Pharmaceuticals Inc’s (NASDAQ:CNCE) Superior ROE?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • Business Wire5 months ago

    Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial evaluating CTP-543. The protocol amendment provides for additional patients to be enrolled in the trial in order to evaluate a 12 mg dose of CTP-543 or placebo twice daily for 24 weeks. In the third quarter of 2018, an independent Data Monitoring Committee (DMC) conducted a planned interim safety data review after patients in the trial had been dosed with an 8 mg dose of CTP-543 or placebo twice daily for at least 12 weeks.

  • Business Wire6 months ago

    Concert Pharmaceuticals to Present at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences: